reports
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study m...
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion, and nasal polyps in patients a...
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi...
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique... ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique ; la demande supplémentaire de licence de mise sur le marché (sBLA) a été acceptée pour examen prioritaire par la FDA Les données de phase 3 qui v...
- Luis Arredondo
SACYR: 3Q’25 RESULTS (ANÁLISIS BANCO SABADELL)
3Q'25 vs. 3Q'24 Results Sales: € 1.175 Bn (2.8% vs. 3.1% BS(e) and 1.3% consensus); EBITDA: € 371 M (27.7% vs. 23.0% BS(e) and 20.1% consensus); EBIT: € 273 M (1.2% vs. 15.2% BS(e) and 20.2% consensus); Net Profit: € 31 M (41.5% vs. 35.1% BS(e) and 70.7% consensus). 9M'25 vs. 9M'24 Results Sales: € 3.412 Bn (4.6% vs. 4.7% BS(e) and 4.0% consensus); EBITDA: € 1.018 Bn (7.4% vs. 6.0% BS(e) and 5.1% consensus); EBIT: € 737 M (-15.2% vs. -10.9% BS(e) and -9.3% consensus); Net Profit: € 62 M (-16.2%...
- Luis Arredondo
SACYR: RDOS. 3T’25 (ANÁLISIS BANCO SABADELL)
Rdos. 3T'25 vs 3T'24: Ventas: 1.175 M euros (2,8% vs 3,1% BS(e) y 1,3% consenso); EBITDA: 371 M euros (27,7% vs 23,0% BS(e) y 20,1% consenso); EBIT: 273 M euros (1,2% vs 15,2% BS(e) y 20,2% consenso); BDI: 31 M euros (41,5% vs 35,1% BS(e) y 70,7% consenso). Rdos. 9M'25 vs 9M'24: Ventas: 3.412 M euros (4,6% vs 4,7% BS(e) y 4,0% consenso); EBITDA: 1.018 M euros (7,4% vs 6,0% BS(e) y 5,1% consenso); EBIT: 737 M euros (-15,2% vs -10,9% BS(e) y -9,3% consenso); BDI: 62 M euros (-16,2% vs -18,2% BS...
- Research Department
IBERIAN DAILY 07 NOVEMBER + 3Q'25 RESULTS. HIGHLIGHTS AND REST OF PREV...
NEWS SUMMARY: ACS, AMADEUS, CELLNEX, IAG, SACYR. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Doubts persist With the results campaign entering the final stretch, the main European indices closed with losses, with the IBEX standing out as the best performer, remaining at around 16,100. In the STOXX 600, Basic Mate...
- Research Department
INFORME DIARIO 07 NOVIEMBRE + RDOS. ESPAÑA Y EUROPA 3T’25. IDEAS DESTA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACS, AMADEUS, CELLNEX, IAG, SACYR. EUROPA: BAYER. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. Se mantienen las dudas Con la campaña de resultados entrando en su recta final, los principales índices europeos cerraron con pérdidas, destacando...
- Alvaro del Pozo
TELEFÓNICA: COMENTARIOS A LA PRESENTACIÓN DEL CMD'25 (ANÁLISIS BANCO S...
Los comentarios de la compañía en la presentación del CMD’25 celebrado ayer estuvieron muy centrados en la rebaja del guidance’25 de FCF y su evolución esperada, así como en las implicaciones de esta evolución para la nueva política de dividendos. Destacamos:
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
- Research Department
IBERIAN DAILY 05 NOVEMBER + 3Q’25 RESULTS. HIGHLIGHTS AND REST OF PREV...
NEWS SUMMARY: GRIFOLS, TELEFÓNICA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Stock markets tentative By contrast to Monday, yesterday stock markets ended better than they opened, although most ended in the red, with tech stocks linked to AI leading the drops after the rally over the past few weeks. In the STOXX 6...
- Research Department
INFORME DIARIO 05 NOVIEMBRE + RDOS. ESPAÑA Y EUROPA 3T’25. IDEAS DESTA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: GRIFOLS, TEEFÓNICA. EUROPA: AHOLD DELHAIZE, BMW. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. Las bolsas dudan A diferencia del lunes, las bolsas fueron de menos a más, aunque la mayoría terminaron en negativo con los valores tecnológicos li...
- James Ratzer
- James Ratzer
Telefonica (Neutral) CMD Quick Take: After all the hype, just a profi...
Telefonica’s CMD has been just over 9 months in the making – and sadly it isn’t yet clear where the story now goes from here. The new guidance now implies no margin growth or capital efficiency improvement over the next three years – but exactly how the higher level of investment will support longer-term growth beyond 2028 is unclear.
- Oliver Metzger
- Thomas Zlowodzki
- Wim Gille
FME FRESENIUS MEDICAL CARE AG
EDEN EDENRED SA
DBK DEUTSCHE BANK AG
ULVR UNILEVER PLC
MMK MAYR-MELNHOF KARTON AG
PHIA KONINKLIJKE PHILIPS N.V.
GEBN GEBERIT AG
NXT NEXT PLC
RY4C RYANAIR HOLDINGS PLC
NEM NEMETSCHEK SE
ARCAD ARCADIS NV
EVK EVONIK INDUSTRIES AG
COLO B COLOPLAST A/S CLASS B
SNP PETROM S.A.
BP. BP P.L.C.
BIM BIOMERIEUX SA
TEF TELEFONICA SA
BNTX BIONTECH SE
AMRZ AMRIZE AG
AAL ANGLO AMERICAN PLC
- Carole Braudeau
- Oliver Metzger
- Thomas Zlowodzki
- Wim Gille
FME FRESENIUS MEDICAL CARE AG
EDEN EDENRED SA
DBK DEUTSCHE BANK AG
ULVR UNILEVER PLC
MMK MAYR-MELNHOF KARTON AG
PHIA KONINKLIJKE PHILIPS N.V.
GEBN GEBERIT AG
NXT NEXT PLC
RY4C RYANAIR HOLDINGS PLC
NEM NEMETSCHEK SE
ARCAD ARCADIS NV
EVK EVONIK INDUSTRIES AG
COLO B COLOPLAST A/S CLASS B
SNP PETROM S.A.
BP. BP P.L.C.
BIM BIOMERIEUX SA
TEF TELEFONICA SA
BNTX BIONTECH SE
AMRZ AMRIZE AG
AAL ANGLO AMERICAN PLC
- Carole Braudeau
- Alvaro del Pozo
TELEFÓNICA: RDOS. 3T’25 Y CMD’25 (ANÁLISIS BANCO SABADELL)
Rdos. 3T'25 vs 3T'24: Ventas: 8.958 M euros (-10,6% vs -10,7% BS(e) y -10,7% consenso); EBITDA: 3.071 M euros (+4,2% vs +3,5% BS(e) y +3,2% consenso); EBIT: 952,0 M euros (+28,6% vs +55,3% BS(e) y +51,6% consenso); BDI: 276,0 M euros (+2660,0% vs +3510,0% BS(e) y +4080,0% consenso). Rdos. 9meses'25 vs 9meses'24: Ventas: 26.971 M euros (-11,3% vs -11,4% BS(e) y -11,4% consenso); EBITDA: 8.966 M euros (-4,3% vs -4,5% BS(e) y -4,6% consenso); EBIT: 3.061 M euros (+9,2% vs +16,2% BS(e) y +15,3% cons...
- Alvaro del Pozo
TELEFÓNICA: 3Q’25 RESULTS & CMD’25 (ANÁLISIS BANCO SABADELL)
3Q'25 vs. 3Q'24 Results Sales: € 8.958 Bn (-10.6% vs. -10.7% BS(e) and -10.7% consensus); EBITDA: € 3.071 Bn (+4.2% vs. +3.5% BS(e) and +3.2% consensus); EBIT: € 952.0 M (+28.6% vs. +55.3% BS(e) and +51.6% consensus); Net Profit: € 276.0 M (+2660.0% vs. +3510.0% BS(e) and +4080.0% consensus); 9M'25 vs. 9M'24 Results Sales: € 26.971 Bn (-11.3% vs. -11.4% BS(e) and -11.4% consensus); EBITDA: € 8.966 Bn (-4.3% vs. -4.5% BS(e) and -4.6% consensus); EBIT: € 3.061 Bn (+9.2% vs. +16.2% BS(e) and +15.3%...
- Stephane Beyazian
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.